New Drug Plus Hormone Therapy for Hormone-Responsive Breast Cancer
Part of Cancer clinical trials.
This trial tests whether a new drug called culmerciclib, combined with hormone therapy, works better than hormone therapy alone for early-stage breast cancer that grows quickly and responds to estrogen. The goal is to shrink tumors before surgery and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old
- Your breast cancer is hormone-receptor positive (ER+) and HER2-negative, confirmed by biopsy
- Your cancer shows rapid cell growth (Ki-67 ≥20%) on biopsy
- You have stage I–IIIA breast cancer and have never received cancer treatment before
- Your heart, liver, and kidney function are adequate, and you have a normal heart rhythm on ECG
- You are able to swallow pills and willing to have a tumor biopsy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called fovinaciclib combined with hormone therapy and HER2-targeting drugs for early-stage breast cancer that has specific markers (HR-positive and HER2-positive). The goal is to shrink tumors before surgery and improve outcomes.
This trial tests a new drug called Culmerciclib for women with advanced HR-positive, HER2-negative breast cancer that has stopped responding to a CDK4/6 inhibitor with hormone therapy. The goal is to see if giving this drug again can help when other treatments no longer work.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
This study tests a new drug called Culmerciclib for women with a certain type of advanced breast cancer that has both hormone receptors and HER2. It’s for patients whose cancer has been stable on at least 4 cycles of prior therapy.
Hear when a new HR+/HER2- Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.